Itron, Inc. - Common Stock (ITRI)
Healthcare › Instruments For Meas & Testing of Electricity & Elec Signals
Price History
Feb 9, 2026 — Mar 30, 2026Investment Snapshot
- Trading 18% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 16.2% — good return on equity
Itron, Inc. - Common Stock (ITRI) is a Healthcare company operating in Instruments For Meas & Testing of Electricity & Elec Signals, listed on the NASDAQ , with a market capitalisation of $3.8 billion . Key value metrics: P/E ratio 13.9, P/B ratio 2.24, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Itron, Inc. - Common Stock — Fundamental Analysis Summary
Itron, Inc. - Common Stock (ITRI) is currently trading 18% above its Graham Number of $72.83, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 13.9x.
On financial health, ITRI shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and solid return on equity of 16.2% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.74.
StockPik's composite Value Score for ITRI is 94/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ITRI reports a moderate gross margin of 36.1% (sector average: 33.5%) and a solid operating margin of 12.8%.
ITRI shows revenue declining at 3% year-over-year, with earnings growing at 26%.